Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma; obe-cel, which is in phase 2 to treat pediatric B-ALL and lupus nephritis; AUTO1/22 to treat pediatric B-ALL, which is phase 1; AUTO8, which is in phase 1 to treat multiple myeloma and light chain amyloidosis; AUTO4/5, which is in preclinical stage to treat peripheral TCL; AUTO6NG, which is in phase 1 to treat neuroblastoma; and AUTO9, which is in preclinical stage to treat acute myeloid leukemia. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.…
Autolus Therapeutics Presents Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026
Autolus Therapeutics (NASDAQ: AUTL) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 752 employees.
The shares were at 0.9073 USD on 20 November 2026, down 33.3% over 52 weeks. Its 52-week range is 0.8963 USD to 2.580 USD: the price is 64.8% below the high and 1.2% above the low.
Its market capitalisation is 241.65M USD.
Autolus Therapeutics reports return on equity of -161.4%, an operating margin of -155.3% and revenue up 94.6% year over year.
Its debt exceeds its cash by 192.80M USD, a debt-to-equity ratio of 0.40. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. The next earnings report is expected on 31 March 2027.